GSK acquires Aiolos Bio in deal worth $1.4 billion

GSK plc has made a strategic move to strengthen its respiratory portfolio with the acquisition of biotechnology company Aiolos Bio, Inc. The deal, valued at $1 billion, with an additional $400 million subject to regulatory milestones, positions GlaxoSmithKline to transform asthma care.

Aiolos Bio has been developing AIO-001, an innovative long-acting anti-TSLP monoclonal antibody. The treatment uses a twice-yearly dosing schedule that significantly improves patient convenience and compliance. Additionally, AIO-001 is not limited to asthma; it also has potential applications in the treatment of chronic sinusitis associated with nasal polyps.

The acquisition comes as AIO-001 enters Phase II clinical trials, demonstrating its promise in a global market of more than 315 million asthma patients. Completion of the GSK acquisition is subject to approval by the Hart-Scott-Rodino Act, which ensures that the transaction complies with antitrust laws and maintains competition in the market.

This article was created and translated with the help of artificial intelligence and reviewed by an editor. For more information, please see our terms and conditions.